[Evaluation of the immunological reactivity of melanoma patients using the rosette formation test].
D003520:Cyclophosphamide / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007104:Immune Adherence Reaction; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008545:Melanoma / Q000188:drug therapy / Q000276:immunology*; D008598:Menstruation; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D011239:Prednisolone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D014750:Vincristine; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D008727:Methotrexate
Otsenka immunologicheskoĭ reaktivnosti bol'nykh melanomoĭ s pomoshch'iu testa rozetkoobrazovaniia